Remove Leads Remove Pharmaceutical manufacturing Remove White Paper
article thumbnail

Building CO2-neutral, defossilised supply chains for chemicals

European Pharmaceutical Review

2 However, most of these efforts relating to catalysis, 3 process waste metrics, 4 lifecycle assessments, 5 pharmaceuticals in the environment 6 and the phase out of substances of concern 7 mainly mitigate the consequences of pharmaceutical manufacturing. Defossilization of pharmaceutical manufacturing. 199‒208.

article thumbnail

What factors are driving life sciences FDI in 2022?

Pharmaceutical Technology

After all, around a third of the world’s leading life sciences corporations have their headquarters in the country. Download the white paper ‘Charleston, USA: A life sciences hub’ here. Discover why global life sciences businesses are choosing this thriving region.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Mitigating the risks of cross-contamination during Oral Solid Dose (OSD) manufacturing

Pharmaceutical Technology

Tablet manufacturing, which is the most common OSD form, takes an API dry powder ingredient and compresses it to form tablets, which can be coated or uncoated. Compared to other dosage forms, tablets are simpler to manufacture, package, and transport.

article thumbnail

Using big data to stabilise pharma supply chains in an age of disruption

Pharmaceutical Technology

In an age of disruption, technology is key to enabling pharmaceutical manufacturers monitor, track and control shipments and their processes. Pharmaceutical firms are changing the way they do business; the future winners will be highly automated and digitalised.

Pharma 52
article thumbnail

The rising importance of containment in small molecule drug development

Pharmaceutical Technology

Despite the current emphasis on biologic medicines, small molecule drugs still dominate the pharmaceutical manufacturing world. Within the small molecule landscape, several trends are shaping the industry’s future, one of the most notable being the rise of high-potency active pharmaceutical ingredients (HPAPIs).